Related Experiment Video

Updated: Aug 29, 2025

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines
08:01

Generation and Expansion of Primary, Malignant Pleural Mesothelioma Tumor Lines

Published on: April 21, 2022

2.0K

KRAS Pathway Alterations in Malignant Pleural Mesothelioma: An Underestimated Player

Lilith Trassl1,2,3, Georgios T Stathopoulos1,2,3

  • 1Institute for Lung Health and Immunity, Helmholtz Munich-German Research Center for Environmental Health, 81377 Munich, Germany.

Cancers
|September 9, 2022
PubMed

Insights

Malignant pleural mesothelioma (MPM) is a rare cancer. This study reveals that the KRAS pathway is frequently altered in MPM, offering new therapeutic targets for this incurable disease.

Area of Science:

  • Oncology
  • Molecular Biology
  • Cancer Research

Background:

  • Malignant pleural mesothelioma (MPM) is a rare, asbestos-induced cancer with unclear molecular drivers.
  • Key mutated genes (BAP1, NF2, CDKN2A, TP53, TSC1) do not solely cause MPM in preclinical models.
  • Previous studies overlooked KRAS pathway involvement due to detection limitations.

Purpose of the Study:

  • To investigate the role of the KRAS pathway in malignant pleural mesothelioma.
  • To identify novel molecular targets for MPM treatment.

Main Methods:

  • Analysis of multiple human MPM datasets.
  • Review of published literature on MPM genetics.
  • Next-generation sequencing data interpretation.

Main Results:

  • KRAS mutations and copy number alterations are prevalent in MPM.
  • Beyond KRAS, other KRAS pathway genes are significantly perturbed in MPM patients.
  • This suggests a broader role for the KRAS pathway in MPM development.

Conclusions:

  • The KRAS pathway is a critical, frequently altered pathway in malignant pleural mesothelioma.
  • Targeting the KRAS pathway presents a promising therapeutic strategy for MPM.
  • Further research into KRAS pathway dysregulation is warranted for MPM treatment development.
Keywords:
MAPKPI3KRASTP53mutationsreceptor tyrosine kinase pathway

More Related Videos

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells11:42

Induction of Mesenchymal-Epithelial Transitions in Sarcoma Cells

Published on: April 7, 2017

9.5K
Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice07:54

Implantation and Monitoring by PET/CT of an Orthotopic Model of Human Pleural Mesothelioma in Athymic Mice

Published on: December 21, 2019

6.9K

Related Concept Videos

The Ras Gene02:38

The Ras Gene

The Ras-gene-encoded proteins are regulators of signaling pathways controlling cell proliferation, differentiation, or cell survival. The Ras-gene family in humans constitutes three primary members—the HRas, NRas, and KRas. These genes code for four functionally distinct yet closely related proteins—the HRas, NRas, KRas4A, and KRas4B. The involvement of mutant Ras genes in human cancer was first discovered in 1982 and is among the most common causes of human tumorigenesis.
Ras is a...
6.4K
MAPK Signaling Cascades01:07

MAPK Signaling Cascades

Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.9K
Abnormal Proliferation02:23

Abnormal Proliferation

Under normal conditions, most adult cells remain in a non-proliferative state unless stimulated by internal or external factors to replace lost cells. Abnormal cell proliferation is a condition in which the cell's growth exceeds and is uncoordinated with normal cells. In such situations, cell division persists in the same excessive manner even after cessation of the stimuli, leading to persistent tumors. The tumor arises from the damaged cells that replicate to pass the damage to the...
4.6K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.9K
PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.9K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.4K